Almorexant HCl

Synonyms: ACT-078573 HCl

Almorexant HCl (ACT-078573) is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor, respectively. Phase 3.

Almorexant HCl Chemical Structure

Almorexant HCl Chemical Structure

CAS: 913358-93-7

Selleck's Almorexant HCl has been cited by 4 Publications

1 Customer Review

Purity & Quality Control

Batch: Purity: 99.99%
99.99

Choose Selective OX Receptor Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO Function assay 30 mins Displacement of [125I]-Orexin A from human OX2R expressed in CHO cells after 30 mins by topcount analysis, Ki = 0.0047 μM. 25267004
CHO Function assay Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium release, IC50 = 0.008 μM. 26317591
CHO Function assay Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay, IC50 = 0.008 μM. 23719231
CHO Function assay Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of orexin-A-induced intracellular calcium release, IC50 = 0.013 μM. 26317591
CHO Function assay Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay, IC50 = 0.013 μM. 23719231
Click to View More Cell Line Experimental Data

Biological Activity

Description Almorexant HCl (ACT-078573) is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor, respectively. Phase 3.
Features Orally bioavailable orexin receptor antagonist that has been tested in Phase III clinical trials for treatment of Insomnia.
Targets
OX2 receptor [1] OX1 receptor [1]
3.4 nM 6.6 nM
In vitro
In vitro Almorexant inhibits the increase in intracellular Ca2+ induced by 10 nM human orexin-A in Chinese hamster ovary cells with IC50 of 16 nM (rat) and 13 nM (human) for the OX1 receptor and 15 nM (rat) and 8 nM (human) for the OX2 receptor. [1]
Experimental Result Images Methods Biomarkers Images PMID
Western blot PhosphoTyr / SHP2 29467942
Growth inhibition assay Tumor volume 29467942
IHC OX1R / Activated caspase-3 H&E staining 29467942
Immunofluorescence BDNF / NPY NPY / ORX-A 32066707
Representative autoradiograms LC / TMN / DRN 22768296
In Vivo
In vivo Almorexant (300 mg/kg p.o.) decreases alertness, and increases electrophysiological indices of both non-REM and REM sleep in male Wistar rats. In dogs, Almorexant (100 mg/kg p.o.) causes somnolence and increases surrogate markers of REM sleep. [1] Almorexant induces a robust antidepressant-like effect and the restoration of stress-related HPA axis defect independently from a neurogenic action. [2] In addition, Almorexant also reduces ethanol self-administration in high-drinking rodent models. [3]
Animal Research Animal Models Wistar rats.
Dosages ~300 mg/kg
Administration p.o.

Chemical lnformation & Solubility

Molecular Weight 549.02 Formula

C29H32ClF3N2O3

CAS No. 913358-93-7 SDF Download Almorexant HCl SDF
Smiles CNC(=O)C(C1=CC=CC=C1)N2CCC3=CC(=C(C=C3C2CCC4=CC=C(C=C4)C(F)(F)F)OC)OC.Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 72 mg/mL ( (131.14 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Almorexant HCl | Almorexant HCl supplier | purchase Almorexant HCl | Almorexant HCl cost | Almorexant HCl manufacturer | order Almorexant HCl | Almorexant HCl distributor